Trial Profile

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary)
Indications Carcinoma; Chondrosarcoma; Endometrial cancer; Gastric cancer; Liver cancer; Nasopharyngeal cancer; Oesophageal cancer; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions; Biomarker
Sponsors Shanghai Junshi Biosciences

Most Recent Events

22 Nov 2024 Status changed from active, no longer recruiting to completed.
12 Dec 2021 Status changed from recruiting to active, no longer recruiting.
28 Sep 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com